Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Nivolumab, Tadalafil and Oral Vancomycin in Refractory Liver Cancers
NCT03785210Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jun 2019
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies, Cyclic Peptides, Antimicrobial Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, tadalafil, vancomycin in hepatocellular carcinoma (HCC), metastatic colorectal cancer (mCRC), sponsored by National Cancer Institute. Started Jun 2019; status: terminated.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03785210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03785210.